We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Angiopoietin-Like 2 Is a Biomarker for Diabetic Foot Patients

By LabMedica International staff writers
Posted on 14 Jan 2021
Print article
Image: Human Total Angiopoietin ELISA assay (Photo courtesy of Immuno-biological laboratories Co).
Image: Human Total Angiopoietin ELISA assay (Photo courtesy of Immuno-biological laboratories Co).
Diabetic foot ulcers (DFUs) are one of the common complications in type 2 diabetes mellitus
patients and are chartered by lower extremity vascular obstructions, persistent foot infections, ulcers, and deep tissue destruction.

Circulating angiopoietin-like 2 (ANGPTL2) protein levels are known to be significantly increased in numerous chronic inflammatory diseases and are associated with the diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.

Endocrinologists at Beijing Luhe Hospital (Beijing, China) recruited a total of 68 participants with type 2 diabetes mellitus (T2DM) including 28 patients with DFU and 40 diabetic patients without DFUs. The diagnosis of T2DM was based on the 1999 World Health Organization Criteria, which fulfills random blood glucose ≥11.1 mmol/L and/or fasting blood glucose (FBG) ≥ 7.0 mmol/L and/or 2 hour blood glucose, during an oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L.

Routine laboratory measurements were performed, including fasting plasma glucose (FBG, mmol/L), alanine transaminase (ALT,U/L), aspartate transaminase (AST,U/L), glutamyl transpeptidase (γ-GT,U/L), triglyceride (TG, mmol/L), total cholesterol (CHO, mmol/L), low density lipoprotein cholesterol (LDL-C, mmol/L), high density lipoprotein cholesterol (HDL-C, mmol/L), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (WBC). Serum ANGPTL2 was measured by using a commercially available human ELISA kits (Immuno-biological laboratories Co., Ltd., Fujioka-Shi, Japan) and Vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN, USA).

The scientists reported that serum levels of ANGPTL2 were significantly higher in patients with DFUs than those in diabetic control ((T2DM versus DFU: 4.221 ± 1.301 versus 6.561 ± 2.335 μg/L). Serum ANGPTL2 levels were higher in the advanced stages of DFUs. Spearman correlation analysis revealed strong positive associations of ANGPTL2 with CRP, VEGF and ESR in all subjects. In addition, serum ANGPTL2 was still positively correlated with DFUs stage after adjusting the risk factors. After adjusting for age, sex, HbA1c and duration of diabetes, ANGPTL2 was found to be independently associated with the presence of DFUs.

The authors concluded that circulating ANGPTL2 levels are an independent risk factor for DFUs and are closely related to the severity of diabetic foot. ANGPTL2 may play important roles in the development of DFUs. The study was originally published on November 30, 2020 in the journal BMC Endocrine Disorders.

Related Links:
Beijing Luhe Hospital
Immuno-biological laboratories Co., Ltd
R&D Systems


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.